新医学2025，Vol.56Issue(2)：155-167,13.DOI:10.12464/j.issn.0253-9802.2024-0470
甲状腺癌靶向药物的耐药机制
Mechanisms of drug resistance to targeted drugs in thyroid cancer
摘要
Abstract
For well-differentiated and early-stage thyroid cancer,conventional treatment options such as surgery,thyroid-stimulating hormone suppression therapy,and radioactive iodine therapy can usually significantly extend patients'overall survival and progression-free survival,with prognosis approaching that of the general population.In contrast,for advanced or undifferentiated thyroid cancer that cannot be surgically resected or is unresponsive to radioactive iodine treatment,systemic therapy is typically required.Traditional cytotoxic chemotherapy or external radiation therapy has limited efficacy in these patients.Over the past decade,targeted therapies for thyroid cancer have undergone rapid development.Despite these treatments yielding promising results,many patients with advanced thyroid cancer ultimately experience disease progression due to acquired resistance.In this paper,we summarize the mechanisms of resistance to targeted drugs in thyroid cancer and explore strategies to overcome resistance,aiming to provide reference for future clinical practice in targeted therapy and guide directions for subsequent research.关键词
甲状腺癌/靶向治疗/耐药/丝裂原活化蛋白激酶/鼠类肉瘤病毒癌基因同源物B1Key words
Thyroid cancer/Targeted therapy/Resistance/Mitogen-activated protein kinase(MAPK)/V-raf murine sarcoma viral oncogene homolog B1(BRAF)引用本文复制引用
文昕云,吴珏堃..甲状腺癌靶向药物的耐药机制[J].新医学,2025,56(2):155-167,13.基金项目
广东省自然科学基金(2018A030313671) （2018A030313671）
广东省援疆科技特派员项目(KTPYJ2022006) （KTPYJ2022006）
